1-对氯苄基-2-咪唑甲醇 | 175203-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-对氯苄基-2-咪唑甲醇
• 中文别名: 1-(4-氯苄基)-1H-咪唑-2-基)甲醇；1-(4-氯苄基)-2-咪唑甲醇
• 英文名称: [1-(4-chlorobenzyl)-1H-imidazol-2-yl]methanol
• 英文别名: [1-[(4-chlorophenyl)methyl]imidazol-2-yl]methanol
• CAS: 175203-53-9
• 化学式: C₁₁H₁₁ClN₂O
• mdl: MFCD00102570
• 分子量: 222.67
• InChiKey: WBQUIVPYPWINGE-UHFFFAOYSA-N

物化性质

• 沸点：
  384.6±27.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090
• 危险类别：
  IRRITANT

文献信息

• [EN] ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE<br/>[FR] ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE
  申请人：UNIV LONDON

  公开号：WO2000027394A1

  公开（公告）日：2000-05-18

  The present invention describes the use of pyrazole or indazole derivates as activators of soluble guanylate cyclase. Some compounds disclosed are novel. All activators are vasodilators and/or inhibit platelet aggregation and are therefore useful in the treatment of peripheral vascular diseases such as hypertension, angina pectoris or atherosclerosis, or in the treatment of prevention of glaucoma, preeclampsia, Raynaud's syndrome, stroke or erectile disfunctions.

  本发明描述了将吡唑或吲唑衍生物用作可溶性鸟苷酸环化酶的激活剂。其中一些化合物是新颖的。所有激活剂均为血管扩张剂和/或抑制血小板聚集剂，因此可用于治疗外周血管疾病，如高血压、心绞痛或动脉粥样硬化，或用于预防青光眼、先兆子痫、雷诺综合征、中风或勃起功能障碍。
• Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
  申请人：Amgen Inc.

  公开号：US20130150339A1

  公开（公告）日：2013-06-13

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物或其药学上可接受的盐，它们是电压门控钠通道抑制剂，特别是Nav 1.7的抑制剂。这些化合物用于治疗可通过钠通道抑制治疗的疾病，如疼痛性疾病。同时提供了含有本发明化合物的药物组合物。
• BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS
  申请人：AMGEN, INC.

  公开号：EP2788332A1

  公开（公告）日：2014-10-15
• US9012443B2
  申请人：——

  公开号：US9012443B2

  公开（公告）日：2015-04-21
• [EN] BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS ARYLE ET HÉTÉROARYLE BICYCLIQUES DES CANAUX CALCIQUES
  申请人：AMGEN INC

  公开号：WO2013086229A1

  公开（公告）日：2013-06-13

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. (The Formula I should be inserted here.) The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.